Palomino Laboratories (PALX) Cash & Equivalents (2022 - 2025)
Palomino Laboratories (PALX) posted Cash & Equivalents of $8.1 million for Q4 2025, up 2.85% sequentially from $7.9 million in Q3 2025, and up 5931.21% YoY from $134657.0 in Q4 2024.
Palomino Laboratories (PALX) Cash & Equivalents (2022 - 2025) Analysis & Trends
Palomino Laboratories has reported Cash & Equivalents for 4 years, with the latest figure at $8.1 million in Q4 2025.
- Quarterly Cash & Equivalents rose 5931.21% year-over-year to $8.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.1 million (up 5931.21% YoY) and the FY2025 annual result came in at $8.1 million, up 5931.21% from the prior year.
- Cash & Equivalents rose to $8.1 million in Q4 2025 per PALX's latest filing, from $7.9 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $8.1 million in Q4 2025 and troughed at $322.0 in Q2 2024.
- A 4-year average of $1.5 million and a median of $500.0 in 2022 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2023 and 2025: Cash & Equivalents fell 24.0% in 2023, then surged 2452250.62% in 2025.
- Over 4 years, Cash & Equivalents stood at $500.0 in 2022, then dropped by 24.0% to $380.0 in 2023, then jumped by 35336.05% to $134657.0 in 2024, then jumped by 5931.21% to $8.1 million in 2025.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $8.1 million, $7.9 million, and $1887.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.12 Mn |
| Sep 30, 2025 | 7.90 Mn |
| Jun 30, 2025 | 1,887.00 |
| Mar 31, 2025 | 18,220.00 |
| Dec 31, 2024 | 134,657.00 |
| Sep 30, 2024 | 322.00 |
| Jun 30, 2024 | 322.00 |
| Mar 31, 2024 | 380.00 |
| Dec 31, 2023 | 380.00 |
| Sep 30, 2023 | 380.00 |
| Dec 31, 2022 | 500.00 |